Simulations Plus to Present at LD Micro 10th Annual Main Event on December 6
November 16 2017 - 8:30AM
Business Wire
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of
software for pharmaceutical discovery and development, today
announced that chairman and chief executive officer, Walt Woltosz,
will present at the 10th annual LD Micro Main Event at 4 p.m. PT on
Wednesday, December 6, 2017.
The 10th annual LD Micro Main Event will highlight many of the
most influential companies in the microcap space including top
performers from the past decade, as well as the next generation of
names looking to make their mark. The conference will be held
December 5-7, 2017 at the Luxe Sunset Boulevard Hotel, 11461 Sunset
Boulevard, Los Angeles, CA.
Management will be available during the day on December 6 for
one-on-one meetings. For more information about the conference, or
to schedule a one-on-one meeting with management, please contact
Hayden IR at slp@haydenir.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. We are investors, first
and foremost. What started out as a newsletter highlighting unique
companies has transformed into several influential conferences
annually (Invitational, Summit, and Main Event). In 2015, LD Micro
launched ldmicro.com as a portal to provide exclusive intraday
information on the entire sector, including the first pure microcap
index (LDMi) which covers stocks in North America with market
capitalizations between $50 million and $300 million.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury and nonalcoholic fatty liver disease.
The company is a global leader focused on improving the ways
scientists use knowledge and data to predict the properties and
outcomes of pharmaceutical, biotechnology, and chemical agents. Our
software is licensed to and used in the conduct of drug research by
major pharmaceutical, biotechnology, chemical, and consumer goods
companies and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and
physiology into our software have made us the leading software
provider for physiologically based pharmacokinetic modeling and
simulation. For more information, visit our website at
www.simulations-plus.com.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171116005505/en/
Simulations Plus Investor
RelationsMs. Renee
Bouche661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024